首页> 外文学位 >Evaluation of drug release & anti-bacterial activity of metronidazole from dermatological bases using reduced level of the drug.
【24h】

Evaluation of drug release & anti-bacterial activity of metronidazole from dermatological bases using reduced level of the drug.

机译:使用降低的药物水平评估从皮肤病学基础释放的甲硝唑的药物释放和抗菌活性。

获取原文
获取原文并翻译 | 示例

摘要

To optimize the clinical efficacy of metronidazole from dermatological product, this research has undertaken by evaluating drug release/permeation profile from various dermatological vehicles with reduced amount of drug. The optimized formulations are compared against Commercial gel and Cream.;Formulations containing 0.4% w/w drug were developed using 2 % HPMC gel, Non ionic emulsion and Anionic emulsion as the vehicles. Penetration enhancers using propylene glycol (PG), dimethylsulfoxide (DMSO) and urea at various levels were evaluated. Commercial products 0.75% w/w metronidazole cream and gel respectively were included as a controls for comparison. Studies were carried out with Franz Diffusion Cells using cellulose membrane and human cadaver skin for two and twelve hour studies.;Among the formulations evaluated, the general rank order of drug release from these samples through the cellulose membrane was observed to be HPMC Gel base > Nonionic emulsion base > Anionic emulsion base. In addition, the effects of various penetration enhancers showed variable effects. However the HPMC gel based vehicle showed significant effect in enhancing the drug release in the presence of Urea. The formulation containing 0.4 % w/w metronidazole and 5% w/w Urea gave a maximum drug release of 37.9 % when compared to 21.2% from the commercial gel. And Anionic emulsion base with PG 10 % gave a release about 14% when compared to 7 % commercial cream. These represents a twofold increase in the release of metronidazole from the formulations. Furthermore, these formulations were studies over an extended period of 12 hours , it gave 63 % drug release from HPMC gel base compared to over 32 % from commercial gel and 23.2 % from anionic cream base against 14 % from commercial cream. Finally , these formulation are extended to study on human cadaver skin as diffusion barrier. As expected the drug release from both the formulations tested were significantly reduced due to resistance posed by skin. After 12 hours the drug release from HPMC gel base is 1.13% & commercial gel is 0.57 % and Anionic emulsion base is 2.55 % & commercial cream is 0.79 % . Once again this indicated that the experimental formulation exhibits superior drug release dynamics. The selected formulations were further evaluated for their antibacterial effects using Periodontal bacteria. The results correlated to the in-vitro drug release profile, where both HPMC & Anionic cream exhibited greater zone of inhibition than compared to commercial products.;The release data from all the samples were treated to calculate various physical parameters including diffusion coefficient, permeability coefficient, partition coefficient, steady state flux and lag period etc. Interestingly , the values for the steady state flux and diffusion coefficient were found to be highest from the optimum formulation and the values for the lag time and partition coefficient were lowest. This supports the evidence that the drug from this formulation is readily diffusible to the skin at a steady rate after its application at the site.;In-vitro drug diffusion studies and in-vitro antibacterial studies proved useful in screening various dermatological formulations of Metronidazole compared to commercial products containing 0.75 % gel and cream . The HPMC & Anionic based formulation with reduced level of drug represents more than two fold increase through human cadaver skin and augmented antibacterial activity. This supports that by using an appropriate vehicle and proper incorporation of drug, one can optimize the drug release from topical formulation for maximum therapeutic effect.
机译:为了优化皮肤病产品中甲硝唑的临床疗效,本研究通过评估药物用量减少的各种皮肤病学媒介物的药物释放/渗透特性进行了研究。将优化的制剂与商业凝胶和乳霜进行比较。;使用2%HPMC凝胶,非离子乳剂和阴离子乳剂作为载体开发了含0.4%w / w药物的制剂。使用丙二醇(PG),二甲基亚砜(DMSO)和尿素的各种含量对渗透促进剂进行了评估。分别包括市售产品0.75%w / w的甲硝唑乳膏和凝胶作为对照。用Franz Diffusion Cells用纤维素膜和人体尸体皮肤进行了两个小时和十二小时的研究。;在所评估的制剂中,观察到这些样品通过纤维素膜从药物中释放出来的一般顺序是HPMC凝胶基>非离子乳液基料>阴离子乳液基料。另外,各种渗透促进剂的作用显示出可变的作用。然而,基于HPMC凝胶的媒介物在尿素存在下显示出显着的增强药物释放的作用。与从市售凝胶中获得21.2%的药物释放相比,含有0.4%w / w甲硝唑和5%w / w尿素的制剂的最大药物释放率为37.9%。 PG含量为10%的阴离子乳液基质与7%的市售乳霜相比,释放量约为14%。这些代表甲硝唑从制剂中释放的两倍增加。此外,对这些制剂进行了长达12小时的研究,发现HPMC凝胶中的药物释放率为63%,而商用凝胶中的释放率为32%以上,阴离子霜剂中的释放率为23.2%,而商用霜剂中的释放率为14%。最后,将这些配方扩展到研究人体尸体皮肤作为扩散屏障。如预期的那样,由于皮肤引起的抗性,两种测试制剂的药物释放显着降低。 12小时后,HPMC凝胶基质的药物释放为1.13%,商业凝胶为0.57%,阴离子乳液基质为2.55%,商业乳膏为0.79%。这再次表明实验制剂表现出优异的药物释放动力学。使用牙周细菌进一步评估所选制剂的抗菌作用。结果与体外药物释放曲线相关,其中HPMC和阴离子乳膏均显示出比市售产品更大的抑制范围。;处理所有样品的释放数据以计算各种物理参数,包括扩散系数,渗透系数有趣的是,根据最佳公式,发现稳态通量和扩散系数的值最高,而滞后时间和分配系数的值最低。这证明了该制剂中的药物在现场应用后很容易以稳定的速率扩散到皮肤上。体外药物扩散研究和体外抗菌研究证明可用于筛选各种甲硝唑的皮肤病学制剂到含有0.75%的凝胶和霜的商业产品。降低药物含量的基于HPMC和阴离子的配方通过人体尸体皮肤和增强的抗菌活性代表了两倍以上的增长。这支持通过使用适当的媒介物和适当的药物掺入,可以优化局部制剂的药物释放,以实现最大的治疗效果。

著录项

  • 作者

    Metla, Sushmitha.;

  • 作者单位

    Long Island University, The Brooklyn Center.;

  • 授予单位 Long Island University, The Brooklyn Center.;
  • 学科 Pharmaceutical sciences.;Health sciences.
  • 学位 M.S.
  • 年度 2015
  • 页码 115 p.
  • 总页数 115
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号